Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Prostate Cancer Other Factors-NSAIDs

Principal Investigator
Name
Ann Hsing
Institution
NCI, DCEG, HREB
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
2006-0223
Initial CDAS Request Approval
Jul 1, 2006
Title
Prostate Cancer Other Factors-NSAIDs
Summary
Non-steroidal anti-inflammatory drugs (NSAIDs) may protect against prostate cancer by inducing apoptosis, inhibiting tumor cell proliferation and invasion, and reducing angiogenesis, in part through inhibition of the cyclooxygenase-2 enzyme. Although most epidemiologic studies suggest that NSAID use is inversely associated with prostate cancer, the magnitude and specificity of this association remain unclear. We examined aspirin and ibuprofen use in relation to prostate cancer risk among 29,356 men ages 55 to 74 who were initially screened for prostate cancer from 1993 to 2001 in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. Men were followed from their first screening exam until September 30, 2002, during which 1,338 cases of prostate cancer were identified. Data on NSAID use were collected at baseline by a self-administered questionnaire.
Aims

To determine whether use of NSAIDs is associated with reduced risk of prostate cancer in a large prospective study.

Collaborators

David Chia (UCLA)
Gerald Andriole (Washington University)
Kim Danforth
Timothy Church (University of Minnesota)

Related Publications